A four-gene glycolysis risk model built with machine learning effectively forecasted survival and treatment efficacy for skin cutaneous melanoma patients.
By October 2026, researchers had combined GTEx and TCGA data with machine learning to build a four-gene glycolysis signature for skin cutaneous melanoma. The signature, based on GOT2, CLN6, GYS1, and IDUA, was developed into a risk model reported to forecast patient survival and treatment efficacy, with additional in vitro work on GYS1 and CLN6.
- Impact 30%
- 49
- Evidence 25%
- 95
- Scale 20%
- 35
- Confidence 15%
- 87
- Recency 10%
- 100
Updated Oct 11, 2026 · TRV-2026-1322
ace